According to a recent LinkedIn post from C Ray Therapeutics, the company’s team plans to attend ANZSNM 2026 in Canberra, Australia, from May 15 to 17 and exhibit at Booth #48. The post highlights an interest in engaging with nuclear medicine professionals across radiopharmaceutical development, supply, and clinical translation in the Asia-Pacific region.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The post suggests that C Ray Therapeutics is targeting partnerships related to Cu-64 and Ac-225 supply, as well as discussions around IND-stage CMC challenges. For investors, this outreach may indicate efforts to deepen integration into the regional nuclear medicine value chain, potentially supporting future pipeline development and commercial collaborations.
By emphasizing engagement with stakeholders interested in China’s RDC ecosystem, the post points to a strategic focus on cross-border radiopharmaceutical capabilities. If successful, such networking at ANZSNM 2026 could enhance the company’s position as a CRDMO player in Asia-Pacific and strengthen its long-term business development prospects in theranostics and nuclear medicine.